Compare Hafnia Limited Common Shares (HAFN) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hafnia Limited Common Shares vs 10X Genomics Inc — how do they compare? Hafnia Limited Common Shares trades at $10.59 (market cap $5.76B), while 10X Genomics Inc trades at $71.84 (market cap $9.35B). The key difference: 10X Genomics Inc is the larger of the two by market cap, and Hafnia Limited Common Shares pays a 10.24% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hafnia Limited Common Shares for 0 Days and 10X Genomics Inc for 91 Days on average.
| HAFN | TXG | |
|---|---|---|
Market Cap | $5.76B | $9.35B |
Volume | 1,835,725 | 4,039,449 |
Sector | Industrials | Health |
52-Week High | $10.92 | $97.74 |
52-Week Low | $5.21 | $11.83 |
Typical Hold Time | 0 Days | 91 Days |
Enterprise Value | $6.37B | $8.88B |
Dividend Yield | 10.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HAFN trades at $10.85, down 0.64% on the day, with a neutral technical signal. The company shows strong fundamentals, with a P/E of 8.35 and net income margin of 24.7%. Recent earnings have consistently beaten expectations, and analysts maintain a 100% buy rating. Key developments include a CEO transition and strategic acquisitions.
Outlook is positive due to robust profitability and growth projections, with 2026 revenue expected to reach $2.7B. Risks include market volatility and execution of new strategies. The stock presents a value opportunity with upside potential, supported by strong cash flow and institutional confidence.
TXG trades at $73.10, down 2.78% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $642.82M in 2025 but a net loss of $43.54M, though recent quarters show earnings beats. Analyst consensus is mixed with a $83.30 price target. Positive news includes Atera shipments and a patent victory, but profitability remains a challenge.
The outlook hinges on Atera's commercial success driving future revenue growth and margin improvement. Risks include persistent losses, competitive pressures, and execution delays. Upside potential exists if new platforms gain traction, but investors should weigh high valuation multiples against ongoing unprofitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hafnia Limited Common Shares
Hafnia Limited owns and operates a fleet of product and chemical tankers that transport refined oil products, vegetable oils, and chemicals for oil and chemical companies worldwide, across the Long Range, Medium Range, and Handy tanker segments, headquartered in Singapore.
Read more on HAFN →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
